Literature DB >> 30680511

The association of CAT-262C/T polymorphism with catalase activity and treatment response in juvenile idiopathic arthritis.

Jelena Bašić1, Jelena Vojinović2,3, Tatjana Jevtović-Stoimenov4, Milena Despotović4, Tatjana Cvetković4, Dragana Lazarević2, Gordana Sušić5, Vuk Milošević6, Mina Cvetković3, Dušica Pavlović4.   

Abstract

Oxidative stress is believed to be of great importance for both the etiology and the persistence of juvenile idiopathic arthritis (JIA). The aim of this study was to investigate the association of -262C/T polymorphism of the catalase (CAT) gene with JIA, as well as to evaluate whether this polymorphism can influence plasma CAT activity and outcome in JIA patients treated with etanercept. A total of 154 subjects (60 JIA patients and 94 healthy volunteers) were screened for CAT-262C/T gene polymorphism using the polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) method. Plasma CAT activity was determined using the spectrophotometric method according to Goth, prior to and 12 months after anti-TNF (etanercept) therapy. Clinical outcome was assessed using the JIA ACR (American College of Rheumatology) response criteria. The genotype and allele frequency distributions of CAT-262C/T polymorphism in the patients were significantly different from those of the controls (p = 0.014, p = 0.006). The TT genotype (polymorphic homozygous) was associated with a 4.36-fold higher likelihood of having JIA (95% CI 1.545-12.323, p = 0.005) as compared to the CC genotype (wild-type). At month 12 of treatment, JIA patients, carriers of the CC genotype, showed significantly higher plasma CAT activity (p = 0.004) and achieved the JIA ACR 70 response more often (p = 0.003) than the patients, carriers of the CT/TT genotype. This is the first study implying the possible association of CAT-262C/T polymorphism with JIA. The results suggest the potential protective effect of the CC genotype, with regard to CAT activity and treatment outcome.

Entities:  

Keywords:  CAT-262C/T polymorphism; Catalase; Etanercept; Juvenile idiopathic arthritis

Mesh:

Substances:

Year:  2019        PMID: 30680511     DOI: 10.1007/s00296-019-04246-3

Source DB:  PubMed          Journal:  Rheumatol Int        ISSN: 0172-8172            Impact factor:   2.631


  35 in total

1.  International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001.

Authors:  Ross E Petty; Taunton R Southwood; Prudence Manners; John Baum; David N Glass; Jose Goldenberg; Xiaohu He; Jose Maldonado-Cocco; Javier Orozco-Alcala; Anne-Marie Prieur; Maria E Suarez-Almazor; Patricia Woo
Journal:  J Rheumatol       Date:  2004-02       Impact factor: 4.666

2.  A simple method for determination of serum catalase activity and revision of reference range.

Authors:  L Góth
Journal:  Clin Chim Acta       Date:  1991-02-15       Impact factor: 3.786

3.  Question 2: Etanercept or adalimumab: which is a better biological therapy for juvenile idiopathic arthritis?

Authors:  Harriet Hunter
Journal:  Arch Dis Child       Date:  2018-09-27       Impact factor: 3.791

4.  Efficacy of etanercept for the treatment of juvenile idiopathic arthritis according to the onset type.

Authors:  Pierre Quartier; Pierre Taupin; Franck Bourdeaut; Irène Lemelle; Pascal Pillet; Michel Bost; Jean Sibilia; Isabelle Koné-Paut; Sylvie Gandon-Laloum; Marc LeBideau; Brigitte Bader-Meunier; Richard Mouy; Marianne Debré; Paul Landais; Anne-Marie Prieur
Journal:  Arthritis Rheum       Date:  2003-04

5.  Vitamin E, thiobarbituric acid reactive substance concentrations and superoxide dismutase activity in the blood of children with juvenile rheumatoid arthritis.

Authors:  M Sklodowska; J Gromadzińska; M Biernacka; W Wasowicz; P Wolkanin; A Marszalek; H Brózik; K Pokuszyńska
Journal:  Clin Exp Rheumatol       Date:  1996 Jul-Aug       Impact factor: 4.473

6.  Oxidant-antioxidant imbalance in blood of children with juvenile rheumatoid arthritis.

Authors:  V Araujo; C Arnal; M Boronat; E Ruiz; C Domínguez
Journal:  Biofactors       Date:  1998       Impact factor: 6.113

7.  Two-year Efficacy and Safety of Etanercept in Pediatric Patients with Extended Oligoarthritis, Enthesitis-related Arthritis, or Psoriatic Arthritis.

Authors:  Tamas Constantin; Ivan Foeldvari; Jelena Vojinovic; Gerd Horneff; Ruben Burgos-Vargas; Irina Nikishina; Jonathan D Akikusa; Tadej Avcin; Jeffrey Chaitow; Elena Koskova; Bernard R Lauwerys; Inmaculada Calvo Penades; Berit Flato; Maria Luz Gamir; Hans-Iko Huppertz; Juan Jose Jaller Raad; Katerina Jarosova; Jordi Anton; Marie Macku; William J Otero Escalante; Lidia Rutkowska-Sak; Ralf Trauzeddel; Patricia J Velez-Sanchez; Carine Wouters; Joseph Wajdula; Chuanbo Zang; Jack Bukowski; Deborah Woodworth; Bonnie Vlahos; Alberto Martini; Nicolino Ruperto
Journal:  J Rheumatol       Date:  2016-03-01       Impact factor: 4.666

8.  Influence of A-21T and C-262T genetic polymorphisms at the promoter region of the catalase (CAT) on gene expression.

Authors:  Khyber Saify; Iraj Saadat; Mostafa Saadat
Journal:  Environ Health Prev Med       Date:  2016-05-25       Impact factor: 3.674

Review 9.  Human catalase, its polymorphisms, regulation and changes of its activity in different diseases.

Authors:  J Kodydková; L Vávrová; M Kocík; A Žák
Journal:  Folia Biol (Praha)       Date:  2014       Impact factor: 0.906

10.  Experience with etanercept, tocilizumab and interleukin-1 inhibitors in systemic onset juvenile idiopathic arthritis patients from the BIKER registry.

Authors:  Gerd Horneff; Anna Carina Schulz; Jens Klotsche; Anton Hospach; Kirsten Minden; Ivan Foeldvari; Ralf Trauzeddel; Gerd Ganser; Frank Weller-Heinemann; Johannes Perter Haas
Journal:  Arthritis Res Ther       Date:  2017-11-22       Impact factor: 5.156

View more
  2 in total

Review 1.  Recent progress in the treatment of non-systemic juvenile idiopathic arthritis.

Authors:  John M Bridges; Elizabeth D Mellins; Randy Q Cron
Journal:  Fac Rev       Date:  2021-02-26

2.  Genetics of diabetic neuropathy: Systematic review, meta-analysis and trial sequential analysis.

Authors:  Yating Zhao; Ruixia Zhu; Danni Wang; Xu Liu
Journal:  Ann Clin Transl Neurol       Date:  2019-09-26       Impact factor: 4.511

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.